Soluble endoglin, hypercholesterolemia and endothelial dysfunction
Language English Country Ireland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
26520890
DOI
10.1016/j.atherosclerosis.2015.10.003
PII: S0021-9150(15)30150-7
Knihovny.cz E-resources
- Keywords
- Endothelial dysfunction, Hypercholesterolemia, Soluble endoglin,
- MeSH
- Biomarkers blood MeSH
- Antigens, CD blood MeSH
- Endothelium, Vascular metabolism physiopathology MeSH
- Endoglin MeSH
- Hypercholesterolemia blood complications physiopathology therapy MeSH
- Cardiovascular Diseases blood etiology physiopathology therapy MeSH
- Humans MeSH
- Prognosis MeSH
- Receptors, Cell Surface blood MeSH
- Growth Differentiation Factors metabolism MeSH
- Growth Differentiation Factor 2 MeSH
- Signal Transduction MeSH
- Nitric Oxide Synthase Type III metabolism MeSH
- Transforming Growth Factor beta metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Biomarkers MeSH
- Antigens, CD MeSH
- Endoglin MeSH
- ENG protein, human MeSH Browser
- GDF2 protein, human MeSH Browser
- NOS3 protein, human MeSH Browser
- Receptors, Cell Surface MeSH
- Growth Differentiation Factors MeSH
- Growth Differentiation Factor 2 MeSH
- Nitric Oxide Synthase Type III MeSH
- Transforming Growth Factor beta MeSH
A soluble form of endoglin (sEng) is known to be an extracellular domain of the full-length membrane endoglin, which is elevated during various pathological conditions related to vascular endothelium. In the current review, we tried to summarize a possible role of soluble endoglin in cardiovascular pathologies, focusing on its relation to endothelial dysfunction and cholesterol levels. We discussed sEng as a proposed biomarker of cardiovascular disease progression, cardiovascular disease treatment and endothelial dysfunction. We also addressed a potential interaction of sEng with TGF-β/eNOS or BMP-9 signaling. We suggest soluble endoglin levels to be monitored, because they reflect the progression/treatment efficacy of cardiovascular diseases related to endothelial dysfunction and hypercholesterolemia. A possible role of soluble endoglin as an inducer of endothelial dysfunction however remains to be elucidated.
References provided by Crossref.org
Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19
Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts
High soluble endoglin levels do not induce changes in structural parameters of mouse heart
